In short
A new clinical trial is underway to assess the effectiveness and safety of JNJ-81241459, a potential breakthrough medication for individuals suffering from moderate to severe plaque psoriasis. This Phase 2b study aims to compare different doses of the drug against a placebo, offering hope for improved treatment options for those affected by this chronic skin condition.
At a glance
- Drug Name
- JNJ-81241459
- Condition Treated
- Moderate to Severe Plaque Psoriasis
- Trial Phase
- Phase 2b
- Administration
- Oral tablets
- Primary Endpoint
- PASI 75 at Week 12
- Key Inclusion Criteria
- Age ≥18, Plaque Psoriasis diagnosis, BSA ≥10%, PASI ≥12, IGA ≥3
- Key Exclusion Criteria
- Non-plaque psoriasis, drug-induced psoriasis, severe medical conditions, IBD, allergies to JNJ-81241459
What is JNJ-81241459?
JNJ-81241459 is a potential new medicine currently being studied for the treatment of moderate to severe plaque psoriasis. It is undergoing a Phase 2b clinical trial to evaluate its effectiveness and safety. This drug is being developed by Johnson & Johnson Enterprise Innovation Inc. and is administered orally in the form of tablets.
Target Condition: Plaque Psoriasis
Plaque psoriasis is a chronic autoimmune condition that affects the skin. It causes rapid buildup of skin cells, resulting in scaly, itchy, and inflamed patches on the skin. The condition can range from mild to severe, and in moderate to severe cases, it can significantly impact a person's quality of life.
Clinical Trial Details
The ongoing clinical trial for JNJ-81241459 is designed to evaluate the drug's efficacy and safety in treating moderate to severe plaque psoriasis. Here are some key details about the study:
- Study Type: This is a Phase 2b trial, which means it's testing the drug's effectiveness and determining the optimal dosage.
- Study Design: The trial is multicenter (conducted at multiple research sites), randomized (participants are randomly assigned to different groups), double-blind (neither the participants nor the researchers know who is receiving the actual drug or placebo), and placebo-controlled (some participants receive an inactive substance for comparison).
- Main Objective: To evaluate the efficacy of JNJ-81241459 compared with placebo in participants with moderate to severe plaque psoriasis.
- Primary Endpoint: The main measure of success for this trial is achieving a 75% reduction in the Psoriasis Area and Severity Index (PASI 75) at Week 12 of treatment. PASI is a tool used to measure the severity and extent of psoriasis.
Eligibility Criteria
To participate in this clinical trial, patients must meet certain criteria. Here are some of the key inclusion and exclusion criteria:
Inclusion Criteria:
- Age: 18 years or older
- Diagnosed with plaque psoriasis
- Total Body Surface Area (BSA) affected by psoriasis: 10% or more
- Total Psoriasis Area and Severity Index (PASI) score: 12 or higher
- Investigator's Global Assessment (IGA) score: 3 or higher
Exclusion Criteria:
- Having non-plaque forms of psoriasis (e.g., erythrodermic, guttate, or pustular)
- Current drug-induced psoriasis
- Severe, progressive, or uncontrolled medical conditions
- Current diagnosis or history of Inflammatory Bowel Disease (IBD)
- Known allergies or hypersensitivity to JNJ-81241459 or its components
Drug Information
JNJ-81241459 is being tested in different dosages during this clinical trial:
- The drug is administered orally in tablet form.
- Different dosages are being tested, including 50mg and 200mg tablets.
- The treatment period in this study lasts for 12 weeks.
- Some participants will receive a placebo (an inactive substance) for comparison.
Potential Benefits
While the effectiveness of JNJ-81241459 is still being studied, the goal of this treatment is to provide relief for patients with moderate to severe plaque psoriasis. If successful, it could offer several potential benefits:
- Reduction in psoriasis symptoms, such as skin inflammation, scaling, and itching
- Improvement in the appearance of psoriasis plaques
- Better quality of life for patients with moderate to severe plaque psoriasis
- A new oral treatment option, which may be more convenient for some patients compared to other forms of psoriasis treatments
It's important to note that as this drug is still in the clinical trial phase, its full benefits and potential side effects are not yet fully known. Patients interested in this treatment should consult with their healthcare provider and consider participating in clinical trials if eligible.